Comparative transcriptomic analysis of 1200 zelenirstat sensitive and insensitive cell lines identified a myristoylation inhibition sensitivity signature that predicted those cancers most likely to respond to NMT inhibitor therapy [7, 8]. Here, NMT1 is linked to cancer.